Actively Recruiting

Age: 18Years +
FEMALE
NCT06083103

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Led by Centre Paul Strauss · Updated on 2026-02-02

50

Participants Needed

1

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

CONDITIONS

Official Title

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged from 18 years old and over
  • Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment
  • For women of childbearing potential: adequate contraception throughout study participation
  • Enrollment in a concomitant clinical trial is authorized
Not Eligible

You will not qualify if you...

  • Oncological history that could interfere with imaging interpretation, except cervical cancer
  • Proven extra-nodal metastasis before study participation
  • Contraindication to MRI or to injection of gadolinium-based contrast agents
  • Contraindication to lumbo-aortic lymphadenectomy
  • Persons deprived of liberty
  • Minors or patients under guardianship or supervision
  • Patients under judicial protection
  • Patients unable to consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institut de cancérologie Strasbourg Europe

Strasbourg, France, 67033

Actively Recruiting

Loading map...

Research Team

C

Claire VIT

CONTACT

M

Manon VOEGELIN

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here